metricas
covid
Buscar en
Clínica e Investigación en Arteriosclerosis
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis Detección y caracterización de la lipoproteína X en una paciente con colestas...
Información de la revista
Vol. 15. Núm. 3.
Páginas 106-110 (enero 2003)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 15. Núm. 3.
Páginas 106-110 (enero 2003)
Acceso a texto completo
Detección y caracterización de la lipoproteína X en una paciente con colestasis
Lipoprotein-X detection and characterization in a patient with cholestasis
Visitas
10653
E. Zapico-Muñiza, E. Llarguèsb, R. Bonet-Marquésa, O. Jorba-Castanya, J. Julve-Gila,c, J.L. Sánchez-Quesadaa,c, F. Blanco-Vacaa,c,
Autor para correspondencia
fblancova@hsp.santpau.es

Correspondencia: Servei de Bioquímica. Hospital de la Santa Creu i Sant Pau. Sant Antoni Maria Claret, 167. 08025 Barcelona. España.
, J. Ordoñez-Llanosa,d
a Servei de Bioquímica. Hospital de la Santa Creu i Sant Pau. Barcelona. España
b Servei de Medicina. Hospital General de Granollers. Granollers. Barcelona. España
c Institut de Recerca. Hospital de la Santa Creu i Sant Pau. Barcelona. España
d Departament de Bioquímica i Biologia Molecular. Universitat Autònoma de Barcelona. Mollet del Vallès. Barcelona. España.
Este artículo ha recibido
Información del artículo

La lipoproteína X (Lp-X) es una lipoproteína anómala presente en el suero de pacientes con colestasis, deficiencia de lecitina:cholesterol aciltransferasa o disfunción hepática y que puede dificultar el diagnóstico del tipo de hipercolesterolemia que presentan estos pacientes. Se presenta un caso de una paciente hipercolesterolémica (8,59 mmol/l) con obstrucción de vías biliares en las que se ha detectado y aislado Lp-X mediante la utilización de ultracentrifugación secuencial, cromatografía de filtración en gel y electroforesis en geles de poliacrilamida. La contribución del cholesterol asociado a esta lipoproteína se ha cuantificado en 1,14 mmol/l haciendo uso de la diferente reactividad de diferentes métodos existentes para la determinación de colesterol de LDL y HDL y que reconocen o no a la Lp-X. Se concluye que la paciente presenta hipercolesterolemia debido fundamentalmente a aumento de LDL.

Palabras clave:
Lp-X
Colestasis

Lp-X is a special lipoprotein present in the serum of patients with cholestatis, lecithin cholesterol acyltransferase deficiency and hepatic damage. Presence of Lp-X can make difficult the diagnosis of the type of hypercholesterolemia presented by these patients. We describe a patient with primary biliar cirrhosis and hypercholesterolemia (8.59 mmol/L) in which Lp-X has been isolated and characterised by the use of sequential ultracentrifugation, gel-filtration chromatography and polyacrylamide gel electrophoresis. Lp-X associated cholesterol has been quantificated in 1,14 mmol/L by using the different reactivity of different methods used to measured LDL and HDL cholesterol. It is concluded that the patient presents hypercholesterolemia mainly due to increased LDL.

El Texto completo está disponible en PDF
Bibliografía
[1.]
D. Seidel, P. Alaupovic, R.H. Furman, W.J. McConathy.
A lipoprotein characterizing obstructive jaundice II. Isolation and particle characterization of the protein moieties of low density lipoproteins.
J Clin Invest, 49 (1971), pp. 2396-2407
[2.]
D. Seidel.
Lipoproteins in liver disease.
J Clin Chem Clin Biochem, 25 (1987), pp. 541-551
[3.]
S. Ritland, J.P. Blomhoff, E. Ghone.
Lecithin:cholesterol acyl-transferase and lipoprotein-X in liver disease.
Clin Chim Acta, 49 (1973), pp. 251-259
[4.]
J. Witt, M. Ober.
Lp-X in newborns: incidence of positive tests without cholestasis.
J Clin Chem Biochem, 14 (1976), pp. 197-202
[5.]
D. Seidel, P. Alaupovic, R.H. Furman.
A lipoprotein characterizing obstructive jaundice. I. Method for quantitative separation and identification of lipoproteins in jaundiced subjects.
J Clin Invest, 48 (1969), pp. 1211-1223
[6.]
A.K. Wally, D. Seidel.
Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes and in the rat.
J Clin Invest, 74 (1984), pp. 867-879
[7.]
E. Manzato, R. Fellin, G. Baggio, S. Walch, W. Neubeck, D. Seidel.
Formation of lipoprotein-X. Its relationship to bile compounds.
J Clin Invest, 57 (1976), pp. 1248-1260
[8.]
R.M. Glickman, S.M. Sabesin.
Lipoprotein metabolism.
The liver: Biology and Pathobiology, 2nd, pp. 331-354
[9.]
K. O, J. Frohlich.
Role of lecithin: cholesterol acyltransferase and apolipoprotein A-I in cholesterol esterification in lipoprotein-X in vitro.
J Lipid Res, 36 (1995), pp. 2344-2354
[10.]
A.K. Walli, D. Seidel.
Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxi-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes and in the rat.
J Clin Invest, 74 (1984), pp. 867-879
[11.]
E.G. Lymn, P.C. Choy, A. Magil, K. O.
Uptake and metabolism of lipoprotein- X in mesangial cells.
Mol Cell Biochem, 175 (1997), pp. 187-194
[12.]
R.J. Havel, H.A. Eder, J.H. Bragdon.
The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.
J Clin Invest, 34 (1955), pp. 1345-1353
[13.]
G. Franceschini, G. Busnach, G. Chiesa, C.R. Sirtori.
Management of lipoprotein-X accumulation in severe chelestasis by semi-selective LDL apheresis.
Am J Med, 90 (1991), pp. 633-638
[14.]
M.F. Lopes-Virella, P. Stone, S. Ellis, J.A. Colwell.
Cholesterol determinations in high-density lipoproteins separated by three different methods.
Clin Chem, 23 (1977), pp. 882
[15.]
W.T. Friedewald, R.I. Levy, D.S. Fredrickson.
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparativecentrifuge.
Clin Chem, 18 (1972), pp. 499-502
[16.]
A.V. Nichols, R.M. Krauss, T.A. Musliner.
Non-denaturing polyacrylamide gradient gel electrophoresis.
Methods Enzymol, 128 (1986), pp. 417-431
[17.]
U. Laemmli.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature, 227 (1970), pp. 680-683
[18.]
À Marzal-Casacuberta, F. Blanco-Vaca, Y. Ishida, J. Julve-Gil, S. Shen, S. Calvet-Márquez, et al.
Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II.
J Biol Chem, 271 (1996), pp. 6720-6728
[19.]
F. Blanco-Vaca, S.J. Qu, C. Fiol, H.Z. Fan, Q. Pao, A. Marzal-Casacuberta, et al.
Molecular basis of fish-eye disease in a patient from Spain: Characterization of a novel mutation in the LCAT gene and lipid analysis of the cornea.
Arterioscler Throm Vasc Biol, 17 (1997), pp. 1382-1391
[20.]
G. Franceschini, C.R. Sirtori, E. Bosisio, V. Gualandri, G.B. Orsiai, A.M. Mogavero, et al.
Relationship of the phenotypic expresión of the AIMilano apoprotein with plasma lipid and lipoprotein patterns.
Atherosclerosis, 58 (1985), pp. 159-174
[21.]
M.O. Pentikainen, E.M. Lehtonen, P.T. Kovanen.
Aggregation and fusion of modified low density lipoproteins.
J Lipid Res, 37 (1996), pp. 2638-2649
[22.]
M. Burnstein, H.R. Scholnick, R. Morfix.
Rapid method for the isolation oflipoproteins from human serum by precipitation with polyanions.
J Lipid Res, 11 (1970), pp. 583-595
[23.]
H. Sugiuchi, Y. Uji, H. Okabe, Y. Itir, K. Uekama, N. Kayahara, K. Miyauchi.
Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glicol-modified encimes and sulfated -cyclodextrin.
Clin Chem, 41 (1995), pp. 717-723
[24.]
H. Fei, S. Maeda, H. Kirii, S. Fujigaki, N. Mewkawa, H. Fuji, et al.
Evaluation of two different homogeneous assays for LDL-cholesterol in lipoprotein-X-positive serum.
Clin Chem, 46 (2000), pp. 1351-1356
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos